STAT News first reported about Prasad’s departure, saying it came after a number of controversial decisions by the FDA regarding a gene therapy drug.
Related Posts
In a switch, Trump approves the Fed’s decision to hold interest rates steady
Trump praised the Federal Reserve for its decision last week to leave interest rates unchanged
U.S. payrolls increased by 147,000 in June, more than expected
Nonfarm payrolls were expected to increase 110,000 in June. The unemployment rate was forecast to rise to 4.3%.
Philip Morris is a growth stock again as shares hit all-time high on Zyn demand boom
The company’s stock was tracking for a record close and clinched a fresh intraday record.